Non‐alcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy

Tomeno, Wataru; Kawashima, Keigo; Yoneda, Masato; Saito, Satoru; Ogawa, Yasuhiro; Honda, Yoshihiro; Kessoku, Takaomi; Imajo, Kento; Mawatari, Hironori; Fujita, Koji; Hirayasu, Yoshio; Nakajima, Atsushi

doi:10.1111/jgh.12897

Cited by 80 publications

(94 citation statements)

References 29 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They assessed a cohort of 567 North American patients with biopsy-proven NAFLD and demonstrated that subclinical and clinical depression were noted in 53 and 14% of NAFLD patients, respectively, Interestingly, depression was associated with more severe hepatocyte ballooning and patients with subclinical depression had a higher likelihood of having more severe portal fibrosis after adjusting for confounders (Youssef et al, 2013). These results are consistent with another recent study by Tomeno et al (2015), in which NAFLD patients comorbid with MDD were characterized by more severe histological steatosis and higher NAFLD activity score. Moreover, serum aminotransferase, GGT, ferritin, and hs-CRP were dramatically higher in the NAFLD patients with MDD than those without MDD.…”

Section: The Link Between Depression and Cldsupporting

confidence: 93%

“…For example, Tomeno et al (2015) compared the NAFLD clinical response within different stages of MDD, and suggested that NAFLD patients comorbid with MDD had poor response to the 48 weeks standard care for NAFLD. In particular, NAFLD patients with unstable MDD (not in full/partial remission) had severe resistance to the treatment (Tomeno et al, 2015).…”

Section: Implications For the Clinical Management Of Patients With Cldmentioning

confidence: 99%

See 1 more Smart Citation

Depression and Chronic Liver Diseases: Are There Shared Underlying Mechanisms?

Huang

Liu

2017

Front. Mol. Neurosci.

View full text Add to dashboard Cite

The occurrence of depression is higher in patients with chronic liver disease (CLD) than that in the general population. The mechanism described in previous studies mainly focused on inflammation and stress, which not only exists in CLD, but also emerges in common chronic diseases, leaving the specific mechanism unknown. This review was to summarize the prevalence and risk factors of depression in CLD including chronic hepatitis B, chronic hepatitis, alcoholic liver disease, and non-alcoholic fatty liver disease, and to point out the possible underlying mechanism of this potential link. Clarifying the origins of this common comorbidity (depression and CLD) may provide more information to understand both diseases.

show abstract

Section: The Link Between Depression and Cldsupporting

confidence: 93%

Section: Implications For the Clinical Management Of Patients With Cldmentioning

confidence: 99%

Depression and Chronic Liver Diseases: Are There Shared Underlying Mechanisms?

Huang

Liu

2017

Front. Mol. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Other investigators have shown that depression is also affected by many lifestyle factors such as eating, exercise, and sleeping [24]. Consequently, previous studies have indicated an association between depression and NAFLD including histological features [1–4]. Interestingly, we found a decrease in oxy-Hb concentration during tasks in NAFLD patients despite having CES-D scores similar to those of healthy controls.…”

Section: Discussionsupporting

confidence: 40%

“…Although some patients with non-alcoholic fatty liver disease (NAFLD) have depression in addition to a positive association between depression and liver histological severity of NAFLD [1–4], other studies have found no association between depression and NAFLD [5–6]. This discrepancy may result from differences in evaluation methods for depression.…”

Section: Introductionmentioning

confidence: 99%

Reduced brain activity in female patients with non-alcoholic fatty liver disease as measured by near-infrared spectroscopy

et al. 2017

View full text Add to dashboard Cite

Patients with non-alcoholic fatty liver disease (NAFLD) have impaired health-related quality of life including physical and mental state. Near-infrared spectroscopy (NIRS) is a useful tool for evaluation of brain activity and depressive state. This study aimed to determine the brain activity of female NAFLD patients using NIRS. Cerebral oxygenated hemoglobin (oxy-Hb) concentration during a verbal fluency task (VFT) was measured using NIRS in 24 female NAFLD patients and 15 female healthy controls. The Center for Epidemiologic Studies Depression Scale (CES-D) questionnaire was administered to both groups before NIRS. There was no significant difference in CES-D score between groups. However, the oxy-Hb concentration and number of words during the VFT were less in NAFLD compared to healthy controls. The mean value of oxy-Hb concentration during 0–60 s VFT in the frontal lobe was also smaller in NAFLD patients compared to healthy controls (0.082 ± 0.126 vs. 0.183 ± 0.145, P < 0.001). Cerebral oxygen concentration is poorly reactive in response to VFT in female NAFLD patients. This may indicate an association between decreased brain activity and NAFLD regardless of depression.

show abstract

“…For example, the pro-inflammatory cytokines MIF [19,29,57], GRO-α [29], MCP-1 [58] and EN-RAGE [19,29] have been shown to be altered in multiple studies. Similarly, the anti-inflammatory cytokine IL-1ra [14,19,29,59] and the coagulation or acute-phase proteins A2macro [24,60,61,62], factor VII [63], vWF [24,29] and ferritin [19,64,65,66,67,68,69] have also been repeatedly reported to be altered in depression patients. Although we found several immune-/inflammation-related enzymes to be altered in patients including AXL, CK-MB and MMP-3, these changes have not been previously reported in depression.…”

Section: Discussionmentioning

confidence: 99%

Identification of an Immune-Neuroendocrine Biomarker Panel for Detection of Depression: A Joint Effects Statistical Approach

Chan

Cooper²,

Bot³

et al. 2015

Neuroendocrinology

View full text Add to dashboard Cite

Background/Aims: Less than half of depression patients are correctly diagnosed within the primary care setting. Previous proteomic studies have identified numerous immune and neuroendocrine changes in patients. However, few studies have considered the joint effects of biological molecules and their diagnostic potential. Our aim was to develop and validate a diagnostic serum biomarker panel identified through joint effects analysis of multiplex immunoassay profiling data from 1,007 clinical samples. Methods: In stage 1, we conducted a meta-analysis of two independent cohorts of 78 first-/recent-onset drug-naive/drug-free depression patients and 156 controls and applied the 10-fold cross-validation with least absolute shrinkage and selection operator regression to identify an optimal diagnostic prediction model (biomarker panel). In stage 2, we tested the discriminatory performance of this biomarker panel using the naturalistic Netherlands Study of Depression and Anxiety (NESDA) cohort of 468 depression patients and 305 controls. Results: An optimal panel of 33 immune-neuroendocrine biomarkers and gender was selected in the meta-analysis. Testing this biomarker-gender panel using the NESDA cohort resulted in a moderate to good performance to differentiate patients from controls (0.69 < AUC < 0.86), particularly the first-episode patients free of chronic non-psychiatric diseases or medications and following incorporation of sociodemographic covariates (0.76 < AUC < 0.92). Conclusion: Despite the need for additional validation studies, we demonstrated that a blood-based biomarker-sociodemographic panel can detect depression in naturalistic healthcare settings with good discriminatory power. Further refinements of blood biomarker panels aiding in the diagnosis of depression may provide a cost-effective means to increase accuracy of clinical diagnosis within the primary care setting.

show abstract

Non‐alcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy

Cited by 80 publications

References 29 publications

Depression and Chronic Liver Diseases: Are There Shared Underlying Mechanisms?

Depression and Chronic Liver Diseases: Are There Shared Underlying Mechanisms?

Reduced brain activity in female patients with non-alcoholic fatty liver disease as measured by near-infrared spectroscopy

Identification of an Immune-Neuroendocrine Biomarker Panel for Detection of Depression: A Joint Effects Statistical Approach

Contact Info

Product

Resources

About